Axxam and Molecular Health take AI-biology blend to early drug discovery

Italian drug discovery specialist Axxam and German AI firm Molecular Health have struck a strategic alliance aimed at improving the precision and speed of therapeutic target identification across multiple disease areas.

The partnership combines Axxam’s experimental biology capabilities with Molecular Health’s AI-driven platform, creating a workflow that moves seamlessly from digital prediction to lab validation. Together, the firms are offering a full-spectrum discovery engine that they say can reduce early-stage risk and improve outcomes in preclinical and clinical research.

At the heart of the collaboration is the integration of Molecular Health’s Dataome platform into Axxam’s DiscoveryMAXX workflow. Dataome analyzes clinical, phenotypic and molecular datasets using artificial intelligence to uncover disease-linked targets with therapeutic potential. These leads are then validated by Axxam using advanced in-vitro systems, including stem cell-based models designed to reflect human disease biology.